A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer

2020 ◽  
Author(s):  
Otto Metzger Filho ◽  
Anita Giobbie-Hurder ◽  
Nancy U. Lin ◽  
Meredith Faggen ◽  
Steven Come ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Adverse Events ◽  
Cancer Patients ◽  
Phase Ii ◽  
Phase Ii Clinical Trial ◽  
Breast Cancer Patients

A Phase II Clinical Trial of Flutamide in the Treatment of Advanced Breast Cancer

1988 ◽  
Vol 74 (1) ◽  
pp. 53-56 ◽  
Author(s):  
Tiping Zhao ◽  
Guifen He
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Transient Response ◽  
Postmenopausal Breast Cancer ◽  
Phase Ii Clinical Trial ◽  
Advanced Breast ◽  
Breast Cancer Patients

An antiandrogenic agent flutamide was used in the treatment of one male and 14 female postmenopausal breast cancer patients. Only a mild and transient response was seen in 2 female patients. Therefore, flutamide cannot be used solely in the treatment of female postmenopausal breast cancer.

scholarly journals Evaluation of ATOX1 as a Potential Predictive Biomarker for Tetrathiomolybdate Treatment of Breast Cancer Patients with High Risk of Recurrence

Biomedicines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1887
Author(s):  
Stéphanie Blockhuys ◽  
Camilla Hildesjö ◽  
Hans Olsson ◽  
Linda Vahdat ◽  
Pernilla Wittung-Stafshede
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
High Risk ◽  
Cancer Patients ◽  
Phase Ii ◽  
Predictive Biomarker ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Risk Of Recurrence ◽  
Expression Levels

Copper plays a key role in cancer metastasis, which is the most common cause of cancer death. Copper depletion treatment with tetrathiomolybdate (TM) improved disease-free survival in breast cancer patients with high risk of recurrence in a phase II clinical trial. Because the copper metallochaperone ATOX1 was recently reported to drive breast cancer cell migration and breast cancer migration is a critical factor in metastasis, we tested if ATOX1 expression levels in primary tumor tissue could predict the TM treatment outcome of breast cancer patients at high risk of recurrence. We performed ATOX1 immunohistochemical staining of breast tumor material (before TM treatment) of 47 patients enrolled in the phase II TM clinical trial and evaluated ATOX1 expression levels in relation with patient outcome after TM treatment. Our results show that higher ATOX1 levels in the tumor cell cytoplasm correlate with a trend towards better event-free survival after TM treatment for triple-negative breast cancer patients and patients at stage III of disease. In conclusion, ATOX1 may be a potential predictive biomarker for TM treatment of breast cancer patients at high risk of recurrence and should be tested in a larger cohort of patients.

Sign in / Sign up

Export Citation Format

Share Document